Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ECNP: Olanzapine/Fluoxetine Combination for Treatment-Resistant and Psychotic Depression Raises No New Safety Issues By Bruce Sylvester Special to DG News BARCELONA, SPAIN -- October 9, 2002 -- The use of olanzapine/fluoxetine combination therapy with treatment-resistant and psychotic depression patients entails no new safety issues other than those commonly associated with olanzapine and fluoxetine monotherapy. The finding was reported here October 7 at the 15th Congress of the European College of Neuropsychopharmachology (ECNP). "We saw no significant differences in categorical changes in laboratory analytes, vital signs, electrocardiograms or extrapyramidal symptoms. There don’t appear to be a new safety issues in the combination therapy as distinct from the monotherapies," reported lead researcher Sanjay Dube, MD, senior clinical investigator at Lilly Laboratories in Indianapolis, Indiana, United States. The investigators conducted a meta-analysis of safety data of five eight-week double-blind studies involving 762 subjects diagnosed with treatment-resistant depression (three studies with 614 subjects) or psychotic depression (two studies with 148 subjects). Each of the two treatment groups in each study had received olanzapine/fluoxetine combination (OFC) therapy -- olanzapine at 5-20 mg/day and fluoxetine at 20-80 mg/day (447 subjects) -- or olanzapine monotherapy (OLZ) at 5-20 mg/day (315 subjects). Of the adverse events seen at a level of at least 10 percent among the OFC group, there were no statistically significant differences from the OLZ group. A statistically significant but small proportion of OFC subjects (3 percent) showed low supine diastolic blood pressure compared with OLZ subjects (0.7 percent, p=0.032). There were no statistically significant differences between OFC and OLZ subjects with regard to categorical changes in laboratory analytes, electrocardiograms, heart rate and extrapyramidal symptoms. "No significant adverse effects were seen when giving OFC compared with olanzapine monotherapy," the research team reported. "And the OFC safety profile was consistent with those expected for component monotherapies. These results support the acute safety and tolerability of OFC." The research was funded by Lilly Laboratories. E-mail this page to a friend or colleague! To print, use this version